pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
JOURNEY · news · pharmadog
← back to JOURNEY
News mentioning JOURNEY
113
stories
5h
STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
stat
10h
Women travel thousands of miles for a reproductive moonshot. Scientists say they’ve been misled
stat
13h
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
biospace
14h
Can Saudi Arabia's burgeoning biotech hub withstand geopolitical pressures?
biospace
15h
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
biospace
3d
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
biospace
4d
Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series A
fiercebiotech
5d
Opinion: Freezing my eggs showed me just how anti-feminist the fertility industry can be
stat
7d
A virus that afflicts cows makes the jump to a human
stat
7d
The 4 stages of women’s heart health: New framework for doctors and patients
stat
10d
Opinion: It took me 13 years to be diagnosed with MS. Christina Applegate’s misdiagnosis doesn’t surprise me
stat
11d
Critical decisions that spurred these 40 Under 40 winners to success
biospace
13d
AstraZeneca taps Oracle to help improve recruitment for clinical trials
fiercebiotech
14d
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
17d
Iambic CEO on taking an AI drug company public
biopharma dive
18d
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
stat
18d
Belgian startup revives Galapagos CAR-T research
biopharma dive
18d
After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
stat
18d
Kenya reports second Ebola case
stat
18d
Opinion: MyChart said I could opt out of sharing my health data. Figuring out how was maddening
stat
19d
From Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2
fiercebiotech
19d
Why OMass’ $310M series C marks ‘fantastic milestone’ on journey to become ‘Britain’s Big Biotech’
fiercebiotech
19d
Jazz CEO calls on industry to help rebuild momentum for leadership diversity
biospace
24d
‘We’re making a lot of progress’: How Nobel-winning optogenetics is being harnessed by biotechs
fiercebiotech
25d
STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and more
stat
25d
The Nobel boys club (again)
stat
25d
A mother-daughter quest to find fellow members of an ultra-rare genetic community
stat
28d
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
stat
28d
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
stat
28d
Precision for All: Closing the gap between innovation and impact
biopharma dive
← prev
page 1 of 4
next →
